Top-News

Actinium Pharmaceuticals Aktie News

Aktie
WKN:  A2QA48 ISIN:  US00507W2061 US-Symbol:  ATNM Branche:  Biotechnologie Land:  USA
1,43 $
-0,02 $
-1,38%
1,2281 € 05.12.25
Depot/Watchlist
Marktkapitalisierung *
34,10 Mio. €
Streubesitz
77,13%
KGV
-1,02
Index-Zuordnung
-

Actinium Pharmaceuticals News

08.04.25 - PR Newswire
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Actinium Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines - ATNM
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Actinium Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines - ...
07.04.25 - PR Newswire
ATNM Stockholders Should Contact Robbins LLP for Information on How to Lead the Class Action Against Actinium Pharmaceuticals, Inc.
ATNM Stockholders Should Contact Robbins LLP for Information on How to Lead the Class Action Against Actinium Pharmaceuticals, Inc. PR Newswire
07.04.25 - PR Newswire
Shareholders that lost money on Actinium Pharmaceuticals, Inc.(ATNM) should contact The Gross Law Firm about pending Class Action - ATNM
Shareholders that lost money on Actinium Pharmaceuticals, Inc.(ATNM) should contact The Gross Law Firm about pending Class Action - ATNM PR Newswire
04.04.25 - PR Newswire
Actinium Pharmaceuticals, Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before May 27, 2025 to Discuss Your Rights - ATNM
Actinium Pharmaceuticals, Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before May 27, 2025 to Discuss Your Rights - ATNM PR Newswire
03.04.25 - PR Newswire
ATNM Investors Have Opportunity to Lead Actinium Pharmaceuticals, Inc. Securities Fraud Lawsuit
ATNM Investors Have Opportunity to Lead Actinium Pharmaceuticals, Inc. Securities Fraud Lawsuit PR Newswire
01.04.25 - PR Newswire
ATNM INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Actinium Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
ATNM INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Actinium Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class ...
31.03.25 - PR Newswire
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Actinium Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines - ATNM
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Actinium Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines - ...
29.03.25 - PR Newswire
ATNM Investors Have Opportunity to Lead ROSEN, NATIONALLY REGARDED INVESTOR COUNSEL, Encourages Actinium Pharmaceuticals, Inc. Securities Fraud Lawsuit
ATNM Investors Have Opportunity to Lead ROSEN, NATIONALLY REGARDED INVESTOR COUNSEL, Encourages Actinium Pharmaceuticals, Inc. Securities Fraud Lawsuit PR ...
28.03.25 - PR Newswire
Investor Alert: Robbins LLP Informs Stockholders of the Actinium Pharmaceuticals, Inc. Class Action Lawsuit
Investor Alert: Robbins LLP Informs Stockholders of the Actinium Pharmaceuticals, Inc. Class Action Lawsuit PR Newswire
27.03.25 - PR Newswire
Actinium Pharmaceuticals Announces ATNM-400 a Novel Non-PSMA Targeting First in Class Prostate Cancer Radiotherapy Leveraging Actinium-225
Actinium Pharmaceuticals Announces ATNM-400 a Novel Non-PSMA Targeting First in Class Prostate Cancer Radiotherapy Leveraging Actinium-225 PR Newswire
27.03.25 - PR Newswire
Actinium Pharmaceuticals Provides Business Update After Presentation at Trump Mar-A-Lago Club Announcing Novel Non-PSMA Prostate Cancer Radiotherapy ATNM-400 and Outlining Revitalized Clinical Pipeline with 2025 Corporate Objectives
Actinium Pharmaceuticals Provides Business Update After Presentation at Trump Mar-​A-Lago Club Announcing Novel Non-PSMA Prostate Cancer Radiotherapy ATNM-400 and ...
26.03.25 - PR Newswire
Actinium Pharmaceuticals to Present Business Update at Trump Mar-A-Lago Club Today
Actinium Pharmaceuticals to Present Business Update at Trump Mar-​A-Lago Club Today PR Newswire
25.03.25 - PR Newswire
Actinium Pharmaceuticals to Host KOL Investor Call at 8am ET Today to Highlight Revamped Clinical Programs and Expanded Market Opportunities Including Newly Initiated Actimab-A Solid Tumor Program
Actinium Pharmaceuticals to Host KOL Investor Call at 8am ET Today to Highlight Revamped Clinical Programs and Expanded Market Opportunities Including Newly Initiated ...
24.03.25 - PR Newswire
Actinium Pharmaceuticals Announces Supply Agreement with Eckert & Ziegler for Ac-225 Radioisotope to Support Comprehensive Development Activities
Actinium Pharmaceuticals Announces Supply Agreement with Eckert & Ziegler for Ac-225 Radioisotope to Support Comprehensive Development Activities PR Newswire
20.03.25 - PR Newswire
Actinium Pharmaceuticals Announces Research Collaboration with Memorial Sloan Kettering to Support Further Clinical Expansion of Actimab-A's Backbone Therapy Strategy
Actinium Pharmaceuticals Announces Research Collaboration with Memorial Sloan Kettering to Support Further Clinical Expansion of Actimab-A's Backbone Therapy Strategy PR ...
19.03.25 - PR Newswire
Actinium Pharmaceuticals to Host Investor KOL Call with Dr. Ehab Atallah of the Medical College of Wisconsin and Provide a Pipeline Update Highlighting Revamped Clinical Programs and Expanded Market Opportunities for Actimab-A and Iomab-ACT with Clinical Data in 2H:2025
Actinium Pharmaceuticals to Host Investor KOL Call with Dr. Ehab Atallah of the Medical College of Wisconsin and Provide a Pipeline Update Highlighting Revamped Clinical ...
18.03.25 - PR Newswire
Actinium Pharmaceuticals Announces Clinical Trial Program in Solid Tumors Combining Actimab-A with PD-1 Checkpoint Inhibitors KEYTRUDA® and OPDIVO®
Actinium Pharmaceuticals Announces Clinical Trial Program in Solid Tumors Combining Actimab-A with PD-1 Checkpoint Inhibitors KEYTRUDA® and OPDIVO® PR Newswire
17.03.25 - PR Newswire
Actinium Pharmaceuticals Announces Publication of Actimab-A + CLAG-M Trial Results in Patients with Relapsed or Refractory Acute Myeloid Leukemia in the Peer-Reviewed Journal Leukemia
Actinium Pharmaceuticals Announces Publication of Actimab-A + CLAG-M Trial Results in Patients with Relapsed or Refractory Acute Myeloid Leukemia in the Peer-​Reviewed ...
12.03.25 - PR Newswire
Actinium Pharmaceuticals to Participate at the 37th Annual Roth Conference
Actinium Pharmaceuticals to Participate at the 37th Annual Roth Conference PR Newswire
11.03.25 - PR Newswire
Actinium Pharmaceuticals Announces Initiation of Actimab-A Triplet Combination Frontline Trial Under NCI CRADA with Venetoclax and Taiho Oncology's Hypomethylating Agent ASTX-727 in Patients with Newly Diagnosed AML
Actinium Pharmaceuticals Announces Initiation of Actimab-A Triplet Combination Frontline Trial Under NCI CRADA with Venetoclax and Taiho Oncology's Hypomethylating Agent ...

Newssuche

Videos

newspaper
05.12.25 +1,73%
Technical Trading: Gold Zukauf Chance
Gold Long Typ: Turbo Open End WKN: VC5S7W Hebel: 2 Laufzeit: OpenEnd Einstieg: Market ... Mehr »